0001171843-16-007572.txt : 20160202 0001171843-16-007572.hdr.sgml : 20160202 20160202171916 ACCESSION NUMBER: 0001171843-16-007572 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160129 FILED AS OF DATE: 20160202 DATE AS OF CHANGE: 20160202 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOLDENBERG DAVID M CENTRAL INDEX KEY: 0001029578 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 161381961 MAIL ADDRESS: STREET 1: UBS GLOBAL ASSET MANAGEMENT (US) INC. STREET 2: 51 WEST 52ND STREET CITY: NEW YORK STATE: NY ZIP: 10019 4 1 formfour.xml OWNERSHIP DOCUMENT X0306 4 2016-01-29 0 0000722830 IMMUNOMEDICS INC IMMU 0001029578 GOLDENBERG DAVID M C/O IMMUNOMEDICS, INC 300 THE AMERICAN ROAD MORRIS PLAINS NJ 07950 1 1 0 0 See Remarks Common Stock 2016-01-29 4 A 0 29240 0 A 2705232 D Common Stock 2016-01-29 4 F 0 12262 1.88 D 2692970 D Common Stock 2016-01-29 4 A 0 29240 0 A 3281297 I See Footnote Common Stock 2016-01-29 4 F 0 12262 1.88 D 3269035 I See Footnote Represents the settlement of common stock underlying Performance Units that have vested in accordance with the terms of the Performance-Based Restricted Stock Unit Issuance Agreement. Includes a total of 190,000 shares held as joint tenants by the reporting person and his spouse, Ms. Cynthia L. Goldenberg (also known as Cynthia L. Sullivan), President and Chief Executive Officer of the Company. Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is an officer. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein. Chief Scientific Officer, Chief Patent Officer, and Chairman of the BOD /s/ Cynthia L. Sullivan, Attorney-In-Fact 2016-02-02